Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
“Our study showed that patients with PS ≥ 2 had poorer pembrolizumab outcomes with a significantly lower rate of response, progression-free survival (PFS) and overall survival (OS).”